cbdMD, Inc. Expected to Post FY2020 Earnings of ($0.63) Per Share (NYSEAMERICAN:YCBD)

cbdMD, Inc. (NYSEAMERICAN:YCBD) – Stock analysts at Cantor Fitzgerald reduced their FY2020 EPS estimates for shares of cbdMD in a research note issued on Tuesday, May 19th. Cantor Fitzgerald analyst P. Zuanic now expects that the company will earn ($0.63) per share for the year, down from their previous forecast of $0.21. Cantor Fitzgerald has a “Neutral” rating and a $1.80 price target on the stock.

cbdMD (NYSEAMERICAN:YCBD) last released its quarterly earnings data on Monday, May 18th. The company reported $0.42 earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.48. The company had revenue of $9.40 million for the quarter.

Separately, Zacks Investment Research raised shares of cbdMD from a “hold” rating to a “buy” rating and set a $1.00 price objective for the company in a research note on Sunday, May 10th.

Shares of NYSEAMERICAN:YCBD opened at $1.66 on Thursday. cbdMD has a one year low of $0.50 and a one year high of $6.55.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. AdvisorShares Investments LLC acquired a new stake in shares of cbdMD in the fourth quarter valued at about $841,000. State Street Corp grew its position in cbdMD by 6.2% during the fourth quarter. State Street Corp now owns 159,899 shares of the company’s stock worth $361,000 after buying an additional 9,381 shares in the last quarter. Oxford Asset Management LLP acquired a new stake in cbdMD during the fourth quarter worth about $50,000. Lionsbridge Wealth Management LLC acquired a new stake in cbdMD during the fourth quarter worth about $341,000. Finally, Geode Capital Management LLC grew its position in cbdMD by 9.1% during the fourth quarter. Geode Capital Management LLC now owns 158,887 shares of the company’s stock worth $359,000 after buying an additional 13,207 shares in the last quarter.

About cbdMD

cbdMD, Inc produces and distributes various cannibidiol (CBD) products in the United States. It operates through three segments: Products, Licensing, and Entertainment. The Products segment produces and markets CBD tinctures, capsules, gummies, bath bombs, vape oils, topical creams, and animal treats and oils under the cdbMD brand.

Recommended Story: Dividend Achievers

Receive News & Ratings for cbdMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for cbdMD and related companies with MarketBeat.com's FREE daily email newsletter.